• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=21642991).
  

PubMed=21356356; DOI=10.1016/j.ajpath.2010.12.014; PMCID=PMC3070574
Gueugnon F., Leclercq S., Blanquart C., Sagan C., Cellerin L., Padieu M., Perigaud C., Scherpereel A., Gregoire M.
Identification of novel markers for the diagnosis of malignant pleural mesothelioma.
Am. J. Pathol. 178:1033-1042(2011)

PubMed=21540305; DOI=10.1183/09031936.00160210
Roulois D., Vignard V., Gueugnon F., Labarriere N., Gregoire M., Fonteneau J.-F.
Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.
Eur. Respir. J. 38:1117-1126(2011)

PubMed=21642991; DOI=10.1038/ng.855; PMCID=PMC4643098
Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Nat. Genet. 43:668-672(2011)

PubMed=21774103; DOI=10.1097/JTO.0b013e318215a07d
Brevet M., Shimizu S., Bott M.J., Shukla N., Zhou Q., Olshen A.B., Rusch V.W., Ladanyi M.
Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
J. Thorac. Oncol. 6:864-874(2011)

PubMed=26539644; DOI=10.18632/oncotarget.6285; PMCID=PMC4792599
Achard C., Boisgerault N., Delaunay T., Roulois D., Nedellec S., Royer P.-J., Pain M., Combredet C., Mesel-Lemoine M., Cellerin L., Magnan A., Tangy F., Gregoire M., Fonteneau J.-F.
Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
Oncotarget 6:44892-44904(2015)